[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"chd---congenital-heart-disease\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:chd---congenital-heart-disease":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,6,0,[8,46,67,94,119,149],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":23,"studyType":24,"phases":4,"briefSummary":25,"conditions":26,"keywords":28,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":34,"lastUpdatePostDateStruct":35,"startDateStruct":38,"completionDateStruct":40,"leadSponsor":42,"locationsCount":45},"100615985","brain-ultrafast-ultrasound-imaging-100615985",false,"NCT07299721","Brain Ultrafast Ultrasound Imaging","Brain Ultrafast Ultrasound Imaging: Application in Pediatric Cardiology: Brain Ultrafast","Brain Ultrafas","Inclusion Criteria:\n\n* Every patient under 2 years old any sex or gender hospitalised in the congenital heart disease unit of the intensive care and anaesthesia for cardiovascular surgery, CHU de Bordeaux.\n* Open anterior fontanella\n* congenital heart disease\n* cardiac shock necessitating mechanical circulatory support.\n* Social security affiliation\n* Parental or legal guardian's non-opposition\n\nExclusion Criteria:\n\n* Anechoic\n* Allergy to echocardiography gel.","ALL","0 Years","2 Years",{"count":21,"type":22},300,"ESTIMATED","1 Day","OBSERVATIONAL","Congenital heart defects affect 1 in 100 births in France, with rising prevalence due to better care. Despite improved survival, 40% of children post-surgery face neurological impairments, and some of them show brain lesions. Causes include heart defects, genetic syndromes, and surgeries. Some heart defects and support systems increase cerebral risks. Monitoring cerebral perfusion is difficult to assess but emerging ultrafast ultrasound offers real-time, non-invasive blood flow insights.",[27],"CHD - Congenital Heart Disease",[29,30,31,32],"Congenital Heart Disease","Paediatric","Cardiac Imaging","Ultrafast ultrasounf","NOT_YET_RECRUITING","2025-12-09",{"date":36,"type":37},"2025-12-23","ACTUAL",{"date":39,"type":22},"2026-01-01",{"date":41,"type":22},"2029-01-01",{"name":43,"class":44},"University Hospital, Bordeaux","OTHER",1,{"id":47,"slug":48,"hasResults":11,"nctId":49,"briefTitle":50,"officialTitle":51,"acronym":4,"eligibilityCriteria":52,"healthyVolunteers":11,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":53,"targetDuration":23,"studyType":24,"phases":4,"briefSummary":54,"conditions":55,"keywords":56,"overallStatus":58,"whyStopped":4,"lastUpdateSubmitDate":59,"lastUpdatePostDateStruct":60,"startDateStruct":62,"completionDateStruct":64,"leadSponsor":66,"locationsCount":45},"100612558","ultrafast-ultrasound-imaging-in-pediatric-cardiology-100612558","NCT07255144","Ultrafast Ultrasound Imaging in Pediatric Cardiology","Ultrafast Ultrasound Imaging: Application in Pediatric Cardiology: Cardiac Ultrafast","Inclusion Criteria:\n\n* Every patient of CHD department of any age or any sex:\n\n  * Patients with CHD\n  * General population patients in good general health as evidenced by medical history coming to our department for a check-up OR diagnosed with small Atrial Septal Defect or small Patent Foramen Ovale\n* Social security affiliation\n* Parental or legal guardian's non-opposition\n\nExclusion Criteria:\n\n* Arrhythmia\n* Segmental kinetic disorder.\n* Pacemaker or multisite stimulation, defibrillator,\n* Anechoic\n* Allergy to echocardiography gel.",{"count":21,"type":22},"About 13 in 1000 children are born with heart disease. Current tools poorly assess heart filling in children, limiting treatment. This study explores ultrafast ultrasound imaging to measure heart stiffness and perfusion in children with congenital heart disease.",[27],[57,30,31,32],"Congenital heart disease","RECRUITING","2025-11-19",{"date":61,"type":37},"2025-11-28",{"date":63,"type":37},"2025-03-11",{"date":65,"type":22},"2028-03-11",{"name":43,"class":44},{"id":68,"slug":69,"hasResults":11,"nctId":70,"briefTitle":71,"officialTitle":72,"acronym":73,"eligibilityCriteria":74,"healthyVolunteers":11,"sex":17,"minAge":75,"maxAge":76,"enrollmentInfo":77,"targetDuration":4,"studyType":79,"phases":80,"briefSummary":82,"conditions":83,"keywords":84,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":88,"lastUpdatePostDateStruct":89,"startDateStruct":91,"completionDateStruct":92,"leadSponsor":93,"locationsCount":45},"100601829","home-based-cardiovascular-rehabilitation-in-young-patients-with-congenital-heart-disease-the-muscle-your-heart-program-100601829","NCT07115589","Home-based Cardiovascular Rehabilitation in Young Patients With Congenital Heart Disease: the \"Muscle Your Heart\" Program","Impacts of Home-based Cardiovascular Rehabilitation on the Physical Fitness of Children, Adolescents and Young Adults With Congenital Heart Disease: the \"Muscle Your Heart\" Program","Muscletoncoeur","Inclusion Criteria:\n\n* Indication for home cardiovascular rehabilitation given by the referring cardiologist as part of routine care.\n* Follow-up for congenital heart disease in the ACC-CHD classification.\n* Patient aged 8 to 25 years at the time of inclusion.\n* Consent of the adult patient or the parents or legal guardians of the minor patient.\n* Social security affiliation (excluding AME).\n* VO2max and\u002For SV1 \\\u003C -1.64 z-score for patients aged 8 to 17 years or VO2max \\\u003C 80% and\u002For SV1 \\\u003C 55% of theoretical VO2max for patients aged 18 to 25 years\n\nExclusion Criteria:\n\n* Unstable and\u002For severe heart failure: severe heart failure (NYHA functional class IV), recent decompensated heart failure requiring hospitalisation and\u002For any significant change in medication (\\\u003C 3 months before inclusion), systolic ventricle dysfunction (left ventricular or systemic ventricular ejection fraction \\\u003C 50%).\n* Severe hypoxemia: pulse oxygen saturation (SpO2) at rest \\\u003C 85%, and\u002For SpO2 at exercise \\\u003C 80%, and\u002For patient requiring oxygen therapy.\n* Pulmonary hypertension as defined by the 2020 ESC guidelines, whatever the aetiology.\n* Significant systolic right ventricle (sRV) hypertension (Srv pressure \\> 50% of systemic systolic pressure).\n* Uncontrolled arrhythmia: symptomatic arrhythmia treated or untreated at rest and\u002For during exercise, treated arrhythmia with sustained supraventricular or ventricular tachycardia on ECG monitoring or during exercise and\u002For CPET, occurrence or aggravation of any supraventricular or ventricular arrhythmia during exercise and\u002For CPET.\n* Advanced atrioventricular block (degree 2 or 3), occurrence or aggravation of any conduction disorder during exercise and\u002For CPET.\n* Uncontrolled arterial hypertension at rest (blood pressure at rest during the consultation \\> 140\u002F90 mmHg in adults, \\> 95th percentile in children).\n* Acute or recent myocarditis and pericarditis (\\\u003C 3 months).\n* Symptomatic aortic or subaortic stenosis (mean gradient \\> 50 mmHg).\n* Non-corrected coarctation of the aorta (surgical or catheter-based repair) with a clinical systolic gradient \\> 20 mmHg.\n* Dilatation of the aorta (aortic root \\> 40 mm in adults, \\> 2 z-score in children) (http:\u002F\u002Fwww.parameterz.com\u002Fsites\u002Faortic-root) except in the case of repaired CHD with dilatation of the aorta inherent in the malformation and without risk of aortic dissection (tetralogy of Fallot, transposition of the great vessels, pulmonary atresia IVC, common trunk artery).\n* Severe obstructive hypertrophic cardiomyopathy.\n* Acute systemic disease.\n* Recent intracardiac thrombus (\\\u003C 3 months), embolism or thrombophlebitis.\n* Inability to follow instructions and\u002For home rehabilitation and\u002For answer questionnaires, as determined by the investigator.\n* Absolute contraindications for CPET: fever, uncontrolled asthma, respiratory failure, acute myocarditis or pericarditis, uncontrolled arrhythmias causing symptoms or hemodynamic compromise, uncontrolled heart failure, acute pulmonary embolus or pulmonary infarction, and patients with mental impairment leading to inability to cooperate.\n* Inability to undergo the physical intervention: inability to physically exercise, any invasive medical intervention occurring within 6 months preceding the inclusion or scheduled during the 3-month study period (such as cardiac surgery, catheter-based intervention, orthopedic surgery, chemotherapy for cancer, or any other significant medical treatment or intervention, as determined by the investigator).\n* For female patients: pregnancy, planning to become pregnant, or breastfeeding woman following questioning of the patient.\n* Any other clinical and\u002For pharmacological treatment that is believed to interfere with the study or the optimal clinical care.\n* Patients deprived of their liberty due to ongoing legal procedure, adult patients under guardianship or curatorship, or unable to personally express their consent.\n* Patients who have benefited from cardiovascular rehabilitation in the 12 months preceding inclusion.\n* Patient participating or wishing to participate in any interventional clinical research (drug trial, medical device, non-drug trial).","8 Years","25 Years",{"count":78,"type":22},21,"INTERVENTIONAL",[81],"NA","Standard cardiovascular rehabilitation is performed in a medical care and rehabilitation centre. However, it may not be adapted to the patient's profile and there are few medical care and rehabilitation centres specialized in pediatric cardiology. The objective of this study is to evaluate the impact of cardiovascular rehabilitation entirely at home on the physical fitness of young patients with congenital heart disease.",[27],[57,30,85,86,87],"Cardiovascular rehabilitation","Adapted physical activity","Therapeutic patient education","2025-08-06",{"date":90,"type":37},"2025-08-11",{"date":39,"type":22},{"date":39,"type":22},{"name":43,"class":44},{"id":95,"slug":96,"hasResults":11,"nctId":97,"briefTitle":98,"officialTitle":99,"acronym":4,"eligibilityCriteria":100,"healthyVolunteers":11,"sex":17,"minAge":23,"maxAge":101,"enrollmentInfo":102,"targetDuration":4,"studyType":79,"phases":104,"briefSummary":106,"conditions":107,"keywords":4,"overallStatus":58,"whyStopped":4,"lastUpdateSubmitDate":110,"lastUpdatePostDateStruct":111,"startDateStruct":113,"completionDateStruct":115,"leadSponsor":117,"locationsCount":45},"100379157","phase-3-no-during-cpb-in-neonates-to-reduce-risk-of-aki-100379157","NCT04216927","NO During CPB in Neonates to Reduce Risk of AKI","Efficacy of Nitric Oxide Administration During Cardiopulmonary Bypass in Neonates at Reducing the Risk of Acute Kidney Injury","Inclusion Criteria:\n\n* All neonates (≤31 days) undergoing cardiac surgery with CPB for CHD will be deemed eligible for enrollment.\n\nExclusion Criteria:\n\n1. Failure to obtain informed consent from parent\u002Fguardian\n2. Clinical signs of preoperative persistent elevated pulmonary vascular resistance,\n3. Emergency surgery,\n4. Episode of cardiac arrest within 1 week before surgery,\n5. Recent treatment with steroids and\u002For a condition that may require treatment with steroids (excluding steroid administration specifically for CPB),\n6. Use of inhaled NO (iNO) immediately prior to surgery,\n7. Structural renal abnormalities by ultrasound,\n8. Preoperative AKI,\n9. Use of other investigational drugs,\n10. Weight less than \\\u003C2 kg,\n11. Gestational age \\\u003C36 weeks,\n12. Major extracardiac congenital anomalies,\n13. Non-English speakers.","31 Days",{"count":103,"type":22},40,[105],"PHASE3","Acute kidney injury (AKI) following cardiac surgery for congenital heart defects (CHD) in children affects up to 60% of high risk-patients and is a major cause of both short- and long-term morbidity and mortality. Despite effort, to date, no successful therapeutic agent has gained widespread success in preventing this postoperative decline in renal function. Nitric oxide is an intricate regulator of acute inflammation and coagulation and is a potent vasodilator. The investigators hypothesize that nitric oxide, administered during cardiopulmonary bypass (CPB), may reduce the incidence of AKI.",[108,27,109],"AKI","Surgery","2025-07-21",{"date":112,"type":37},"2025-07-24",{"date":114,"type":37},"2023-01-10",{"date":116,"type":22},"2026-06-30",{"name":118,"class":44},"Children's Hospital Medical Center, Cincinnati",{"id":120,"slug":121,"hasResults":11,"nctId":122,"briefTitle":123,"officialTitle":124,"acronym":125,"eligibilityCriteria":126,"healthyVolunteers":11,"sex":17,"minAge":127,"maxAge":128,"enrollmentInfo":129,"targetDuration":4,"studyType":79,"phases":131,"briefSummary":132,"conditions":133,"keywords":134,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":140,"lastUpdatePostDateStruct":141,"startDateStruct":143,"completionDateStruct":145,"leadSponsor":147,"locationsCount":148},"100592811","feasibility-of-home-telemonitoring-of-infants-with-congenital-heart-disease-awaiting-surgery-during-the-first-year-of-life-100592811","NCT06998290","Feasibility of Home Telemonitoring of Infants With Congenital Heart Disease Awaiting Surgery During the First Year of Life","Feasibility of Home Telemonitoring of Infants With Congenital Heart Disease Awaiting Surgery During the First Year of Life: the Blue-Line Pilot Study","Blue-Line","Inclusion Criteria:\n\n* Newborns and\u002For infants aged 0 to 12 months inclusive at the time of diagnosis.\n* With congenital heart disease as defined in the ICD-11 classification.\n* Waiting for an intervention by cardiac surgery or interventional catheterization.\n* Free, informed consent signed by the holder(s) of parental authority.\n* Person affiliated to or benefiting from a social security scheme.\n\nExclusion Criteria:\n\n* Short-term vital prognosis\n* Clinical situation identified at the M3C RCP that contraindicates a return home\n* Family situation identified at the M3C RCP as contra-indicating a return home\n* Extra-cardiac co-morbidities requiring hospitalisation independent of the heart disease (e.g. severe renal failure, neurological deficit, complex immune deficiency, etc.).\n* Limited understanding of parental authority holder(s) \u002F caregivers (non-French speaking, hearing impaired, cognitive impairment or other)\n* Parents unable to give informed consent.\n* Minors with parental authority","0 Months","12 Months",{"count":130,"type":22},20,[81],"Actually, there is no telemonitoring program that includes newborns or infants with congenital heart disease awaiting cardiac intervention. This is a vulnerable period, prone to clinical complications, rehospitalization, parental stress, and requires monitoring with clinical and therapeutic optimization. The aim of the study is to assess the feasibility and acceptability of monitoring newborns and infants with congenital heart disease awaiting cardiac surgery using the Blue-Line home telemonitoring program.",[27],[57,135,136,137,138,139],"Infants","Vulnerability","Home monitoring","Therapeutic education","Digital platform","2025-05-21",{"date":142,"type":37},"2025-05-31",{"date":144,"type":22},"2025-06-01",{"date":146,"type":22},"2027-06-01",{"name":43,"class":44},2,{"id":150,"slug":151,"hasResults":11,"nctId":152,"briefTitle":153,"officialTitle":154,"acronym":4,"eligibilityCriteria":155,"healthyVolunteers":11,"sex":17,"minAge":156,"maxAge":157,"enrollmentInfo":158,"targetDuration":4,"studyType":79,"phases":160,"briefSummary":161,"conditions":162,"keywords":163,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":167,"lastUpdatePostDateStruct":168,"startDateStruct":170,"completionDateStruct":172,"leadSponsor":174,"locationsCount":45},"100589723","bilateral-ultrasound-guided-superficial-parasternal-intercostal-plane-block-versus-erector-spinae-plane-block-100589723","NCT06958120","Bilateral Ultrasound Guided Superficial Parasternal Intercostal Plane Block Versus Erector Spinae Plane Block","Analgesic Efficacy of Bilateral Ultrasound Guided Superficial Parasternal Intercostal Plane Block Versus Erector Spinae Plane Block in Pediatric Patients Undergoing Corrective Cardiac Surgeries - A Randomized Controlled Study","Inclusion Criteria:\n\n* RACHS-1: Categories 1, 2 and 3\n* Patients undergoing corrective cardiac surgeries with midline sternotomy incision.\n* Redo surgeries.\n\nExclusion Criteria:\n\n* Patients whose parents or legal guardians refuse to participate.\n* Preoperative mechanical ventilation.\n* Preoperative inotropic drug infusion.\n* Coagulopathy.\n* Allergy to any of the studied drugs.\n* Severe pulmonary hypertension (\\> 70 mmHg).","6 Months","4 Years",{"count":159,"type":22},50,[81],"Group (A): This group will receive fentanyl infusion at a dose of (0.5μg\u002Fkg\u002Fh) all through the whole operation plus ultrasound guided bilateral superficial parasternal intercostal Plane block which will be done by injecting 0.4ml\u002Fkg (1:1 solution of bupivacaine 0.25% and lidocaine 1%) at each side3.\n\nGroup (B): This group will receive fentanyl infusion at a dose of (0.5μg\u002Fkg\u002Fh) all through the whole operation plus Ultrasound guided bilateral ESPB which will be done by injecting 0.4ml\u002Fkg (1:1 solution of bupivacaine 0.25% and lidocaine 1%) at each side .",[27],[164,165,166],"CHD","Regional anaesthesia","Pain management","2025-05-10",{"date":169,"type":37},"2025-05-13",{"date":171,"type":22},"2025-06",{"date":173,"type":22},"2026-02",{"name":175,"class":44},"Cairo University"]